Detailed studies of the broadly neutralizing antibodies (bNAbs) that underlie the best available
examples of the humoral immune response to HIV are providing important information for …

The development of an effective AIDS vaccine has been challenging because of viral
genetic diversity and the difficulty of generating broadly neutralizing antibodies (bnAbs). We …

Antibodies capable of neutralizing divergent influenza A viruses could form the basis of a
universal vaccine. Here, from subjects enrolled in an H5N1 DNA/MIV-prime-boost influenza …

A central goal of HIV-1 vaccine research is the elicitation of antibodies capable of neutralizing
diverse primary isolates of HIV-1. Here we show that focusing the immune response to …

The epitopes defined by HIV-1 broadly neutralizing antibodies (bNAbs) are valuable templates
for vaccine design, and studies of the immunological development of these antibodies …

The treatment of AIDS with combination antiretroviral therapy (cART) remains lifelong largely
because the virus persists in latent reservoirs. Elimination of latently infected cells could …

Treatment of HIV infection with either antiretroviral (ARV) therapy or neutralizing monoclonal
antibodies (NAbs) leads to a reduction in HIV plasma virus. Both ARVs and NAbs prevent …

Lineage-based vaccine design is an attractive approach for eliciting broadly neutralizing
antibodies (bNAbs) against HIV-1. However, most bNAb lineages studied to date have features …

Extraordinary antibodies capable of near pan-neutralization of HIV-1 have been identified.
One of the broadest is antibody 10E8, which recognizes the membrane-proximal external …

We demonstrate that at least three different promoter variant strains of HIV-1 subtype C
have been gradually expanding and replacing the standard subtype C viruses in India, and …